Meath Callie J, Simon Bindu, Mehta Rohtesh S, Kebriaei Partow, Lin Jamie S
Department of Internal Medicine-Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Clin Kidney J. 2025 Jun 14;18(7):sfaf188. doi: 10.1093/ckj/sfaf188. eCollection 2025 Jul.
Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic cell transplantation that can lead to multiorgan failure, including acute kidney injury (AKI) due to hepatorenal syndrome (HRS)-like physiology. Current supportive measures often fail in preserving renal function, and dialysis is associated with high mortality risk. Terlipressin, a vasopressin analog approved for HRS in cirrhosis, has not been previously described for SOS-AKI. We report the first detailed case of terlipressin improving renal function, restoring diuretic responsiveness, and preventing dialysis in a patient with SOS, highlighting its potential as a therapeutic option for SOS-related renal failure.
窦性阻塞综合征（SOS）是造血细胞移植的一种危及生命的并发症，可导致多器官功能衰竭，包括因肝肾综合征（HRS）样生理状态引起的急性肾损伤（AKI）。目前的支持性措施往往无法保留肾功能，且透析与高死亡风险相关。特利加压素是一种已被批准用于治疗肝硬化HRS的血管加压素类似物，此前尚未见用于SOS-AKI的报道。我们报告了首例特利加压素改善肾功能、恢复利尿反应并预防一名SOS患者透析的详细病例，突出了其作为SOS相关肾衰竭治疗选择的潜力。
